Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001641172-25-004920
Filing Date
2025-04-15
Accepted
2025-04-15 17:30:06
Documents
66
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm   iXBRL 10-K 2168321
2 ex14-1.htm EX-14.1 39933
3 ex19-1.htm EX-19.1 66769
4 ex23-1.htm EX-23.1 3644
5 ex31-1.htm EX-31.1 7564
6 ex31-2.htm EX-31.2 10681
7 ex32-1.htm EX-32.1 3906
8 ex32-2.htm EX-32.2 3971
9 form10-k_001.jpg GRAPHIC 52967
10 form10-k_002.jpg GRAPHIC 36311
  Complete submission text file 0001641172-25-004920.txt   7707396

Data Files

Seq Description Document Type Size
11 XBRL SCHEMA FILE kapa-20241231.xsd EX-101.SCH 47819
12 XBRL CALCULATION FILE kapa-20241231_cal.xml EX-101.CAL 47426
13 XBRL DEFINITION FILE kapa-20241231_def.xml EX-101.DEF 236846
14 XBRL LABEL FILE kapa-20241231_lab.xml EX-101.LAB 464280
15 XBRL PRESENTATION FILE kapa-20241231_pre.xml EX-101.PRE 360566
69 EXTRACTED XBRL INSTANCE DOCUMENT form10-k_htm.xml XML 719790
Mailing Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064
Business Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064 818-404-5541
Kairos Pharma, LTD. (Filer) CIK: 0001962011 (see all company filings)

EIN.: 462993314 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-42275 | Film No.: 25840720
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)